| 1 | TCL1A levels | GCST90470817 | 87.05 |
| 2 | N-delta-acetylornithine levels | GCST90200691 | 82.86 |
| 3 | PARP1/TCL1A ratio | GCST90315602 | 72.74 |
| 4 | FCER2/TREML2 ratio | GCST90314792 | 72.69 |
| 5 | FCRL2 levels | GCST90469206 | 70.77 |
| 6 | FCRL1 levels | GCST90469205 | 65.82 |
| 7 | FCER2 levels | GCST90469199 | 65.15 |
| 8 | Multiple myeloma or monoclonal gammopathy of undetermined significance | GCST90624746 | 65.11 |
| 9 | IL5RA levels | GCST90469600 | 64.78 |
| 10 | CD22 levels | GCST90468610 | 64.12 |
| 11 | Pain in limb | FING00001138 | 63.73 |
| 12 | CD27/TNFRSF13B ratio | GCST90313777 | 63.27 |
| 13 | JCHAIN levels | GCST90469661 | 63.02 |
| 14 | Incidence of bisecting GlcNAc in all fucosylated disialylated structures (GP57) | GCST90668735 | 61.13 |
| 15 | ZNRD2 levels | GCST90471103 | 60.73 |
| 16 | Lymphoid neoplasms (P-cell phenocluster) | GCST90624737 | 59.01 |
| 17 | FCRL5/LY96 ratio | GCST90314803 | 57.53 |
| 18 | TNFRSF13B/TNFRSF9 ratio | GCST90315932 | 56.06 |
| 19 | Systemic lupus erythematosus | GCST90011866 | 56.04 |
| 20 | TCL1A/TNFRSF13C ratio | GCST90315912 | 55.86 |
| 21 | TNFRSF13B/TNFSF13B ratio | GCST90315933 | 54.78 |
| 22 | CD72 levels | GCST90468646 | 54.15 |
| 23 | FCER2/TNFRSF9 ratio | GCST90314791 | 53.95 |
| 24 | Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74) | GCST90668518 | 51.72 |
| 25 | TNFSF13B levels | GCST90470920 | 51.31 |
| 26 | FCER2/FCRL1 ratio | GCST90314789 | 51.16 |
| 27 | CD5L levels | GCST90468640 | 50.95 |
| 28 | Rheumatoid arthritis | GCST90018690 | 49.59 |
| 29 | TNFRSF13C levels | GCST90470906 | 49.46 |
| 30 | KIF22 levels | GCST90469682 | 48.97 |
| 31 | SLAMF1 levels | GCST90274835 | 48.49 |
| 32 | INPP5J levels | GCST90469618 | 48.42 |
| 33 | IL18RAP levels | GCST90469566 | 46.58 |
| 34 | UGDH levels | GCST90471006 | 46.32 |
| 35 | Multiple myeloma | GCST90624747 | 46.01 |
| 36 | SEPTIN3 levels | GCST90470576 | 44.88 |
| 37 | TNFRSF13B levels | GCST90470905 | 44.37 |
| 38 | Paraproteinemia (PheCode 270.32) | GCST90475710 | 41.98 |
| 39 | Monoclonal gammopathy of undetermined significance | GCST90624745 | 41.83 |
| 40 | Non-albumin protein levels | UKBB00000503 | 41.29 |
| 41 | CD22/SEMA7A ratio | GCST90313759 | 40.90 |
| 42 | Other soft tissue disorders, not elsewhere classified | FING00001099 | 40.80 |
| 43 | DTI TBSS FA Sagittal stratum L | GCST90384411 | 40.14 |
| 44 | CR2/TNFRSF13B ratio | GCST90314225 | 38.88 |
| 45 | FCRL5/TNFRSF13B ratio | GCST90314805 | 38.68 |
| 46 | Kela-code for severe mental illness | FING00000707 | 38.07 |
| 47 | Left ventricular end systole inferior wall thickness | GCST90278509 | 37.86 |
| 48 | Rheumatoid arthritis | GCST90132224 | 37.63 |
| 49 | FCER2/TCL1A ratio | GCST90314790 | 37.56 |
| 50 | Physical activity (confirmatory factor analysis Factor 23) | GCST90309357 | 37.32 |
| 51 | CD22/TCL1A ratio | GCST90313760 | 37.05 |
| 52 | ALB/Globulin ratio | UKBB00000020 | 36.82 |
| 53 | CD79B/TNFRSF13B ratio | GCST90313902 | 36.29 |
| 54 | FCRL1/TCL1A ratio | GCST90314795 | 35.32 |
| 55 | FCRL2/TNFRSF13B ratio | GCST90314801 | 35.23 |
| 56 | Primary biliary cholangitis | GCST90061440 | 34.54 |
| 57 | FCRL1/TREML2 ratio | GCST90314797 | 34.52 |
| 58 | Disorders of plasma protein metabolism (PheCode 270.3) | GCST90475709 | 34.44 |
| 59 | FCRL2/SEMA7A ratio | GCST90314800 | 34.12 |
| 60 | Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) | GCST90132227 | 33.62 |
| 61 | Lymphoid neoplasms (somatic mutation group 2 phenocluster) | GCST90624750 | 33.42 |
| 62 | Blood cell traits latent factor 23 (white cell) | GCST90559265 | 33.12 |
| 63 | Urine X-24796 levels in chronic kidney disease | GCST90266800 | 33.06 |
| 64 | Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperium or nerve system disorders (more control exclusions) | FING00000101 | 32.54 |
| 65 | Sleep duration | GCST003839 | 32.32 |
| 66 | TP53BP1 levels | GCST90470936 | 31.12 |
| 67 | CD27/TNFRSF9 ratio | GCST90313778 | 31.09 |
| 68 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 4) | GCST90320823 | 30.98 |
| 69 | Moderate to vigorous physical activity duration | GCST90061422 | 30.79 |
| 70 | Bifidobacterium kashiwanohense abundance in stool | GCST90032226 | 30.31 |
| 71 | MZB1/TNFRSF13B ratio | GCST90315509 | 29.87 |
| 72 | TNFRSF17 levels | GCST90470908 | 29.82 |
| 73 | Chronic lymphocytic leukemia | GCST90624738 | 28.79 |
| 74 | Colitis, primary sclerosing, strict definition | FING00000313 | 28.64 |
| 75 | Lymphocyte count | GCST90002388 | 28.61 |
| 76 | TXNDC15 levels | GCST90470990 | 28.49 |
| 77 | Urticaria | FING00001408 | 28.43 |
| 78 | Lymphoid neoplasms (B-cell phenocluster) | GCST90624736 | 28.23 |
| 79 | Lymphocyte count | GCST004627 | 28.20 |
| 80 | FCRL1/TNFRSF13C ratio | GCST90314796 | 28.15 |
| 81 | Enthesopathies of lower limb, excluding foot | FING00000509 | 27.85 |
| 82 | Blood cell traits latent factor 17 (white cell) | GCST90559259 | 27.77 |
| 83 | PEAR1/TREML2 ratio | GCST90315645 | 27.60 |
| 84 | CTSO levels | GCST90468915 | 27.00 |
| 85 | IDP dMRI ProbtrackX L1 cgc l | GCST90004250 | 26.61 |
| 86 | Fibrosis and cirrhosis of liver | FING00000543 | 26.46 |
| 87 | Lymphocyte count (UKB data field 30120) | GCST90468082 | 26.41 |
| 88 | Lymphocyte count | GCST90002316 | 26.28 |
| 89 | Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000641 | 26.21 |
| 90 | Systemic lupus erythematosus | GCST90014238 | 26.19 |
| 91 | Champagne or white wine consumption (glasses per month) (UKB data field 1578, 4418) | GCST90132986 | 25.94 |
| 92 | CALCOCO1/MAP3K5 ratio | GCST90313605 | 25.92 |
| 93 | Sleep apnea | GCST90475824 | 25.89 |
| 94 | Lymphoid neoplasms (drug group 1 phenocluster) | GCST90624740 | 25.68 |
| 95 | CR2 levels | GCST90468852 | 25.65 |
| 96 | CD83/IL12A_IL12B ratio | GCST90313905 | 25.62 |
| 97 | QPCT/RNASET2 ratio | GCST90315758 | 25.58 |
| 98 | ICAM3/TNFRSF13B ratio | GCST90315124 | 25.57 |
| 99 | FCRL2/LY9 ratio | GCST90314799 | 25.44 |
| 100 | Lymphocyte count | Blood count | UKBB00000411 | 25.34 |
| 101 | IDP T1 FAST ROIs L cerebellum V | GCST90002564 | 25.31 |
| 102 | NINJ1 levels | GCST90470049 | 25.30 |
| 103 | Medication use (immunosuppressants) | GCST90018771 | 25.08 |
| 104 | LILRB1 levels | GCST90469776 | 24.81 |
| 105 | IL5RA/TNFRSF13B ratio | GCST90315164 | 24.50 |
| 106 | X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels | GCST90243619 | 24.48 |
| 107 | PRCP levels | GCST90470314 | 24.17 |
| 108 | TNFRSF13B/TNFRSF13C ratio | GCST90315931 | 24.15 |
| 109 | S100A11/S100A12 ratio | GCST90315798 | 24.08 |
| 110 | Types of physical activity in last 4 weeks - Strenuous sports | Physical activity | UKBB00000874 | 23.85 |
| 111 | Primary biliary cholangitis | GCST003129 | 23.68 |
| 112 | WASL levels | GCST90471070 | 23.67 |
| 113 | Sicca syndrome [Sjögren] | FING00001304 | 23.59 |
| 114 | Biological Sibling: Cancer, Skin | GCST90476369 | 23.52 |
| 115 | BLNK levels | GCST90468448 | 23.44 |
| 116 | Lymphocyte count | GCST90002317 | 23.42 |
| 117 | IL16 levels | GCST90469557 | 23.29 |
| 118 | Lifetime number of sexual partners | Sexual factors | UKBB00000406 | 22.93 |
| 119 | Myasthenia gravis | GCST90432156 | 22.87 |
| 120 | rfMRI connectivity (ICA25 edge 103) | GCST90004746 | 22.83 |
| 121 | CD22/FCER2 ratio | GCST90313756 | 22.63 |
| 122 | SERPINA9 levels | GCST90470588 | 22.62 |
| 123 | F-meat liking (derived food-liking factor) | GCST90094799 | 22.59 |
| 124 | SORT1/ST6GAL1 ratio | GCST90315869 | 22.41 |
| 125 | PLXNA4/USP8 ratio | GCST90315690 | 22.37 |
| 126 | Lymphoid leukemia, chronic (PheCode 204.12) | GCST90475613 | 22.09 |
| 127 | TRAF3 levels | GCST90470957 | 22.02 |
| 128 | CD79B/TNFRSF4 ratio | GCST90313903 | 21.92 |
| 129 | Occupational attainment | GCST90102253 | 21.87 |
| 130 | IGLC2 levels | GCST90469536 | 21.80 |
| 131 | Idiopathic pulmonary fibrosis | FING00000659 | 21.76 |
| 132 | Primary biliary cholangitis (PBC) | FING00001211 | 21.53 |
| 133 | MBL2 levels | GCST90469868 | 21.46 |
| 134 | Time spend outdoors in summer | Sun exposure | UKBB00000817 | 21.38 |
| 135 | PDCD1/TNFRSF8 ratio | GCST90315610 | 21.26 |
| 136 | GART levels | GCST90469303 | 21.26 |
| 137 | PCSK7 levels | GCST90470176 | 20.96 |
| 138 | CRYBB2 levels | GCST90468875 | 20.94 |
| 139 | Pre-existing hypertension complicating pregnancy, childbirth and the puerperium | FING00001203 | 20.90 |
| 140 | MMP1/SERPINB6 ratio | GCST90315462 | 20.70 |
| 141 | Qualifications - Other professional qualifications eg: nursing, teaching | Education | UKBB00000732 | 20.53 |
| 142 | CCL5/TACC3 ratio | GCST90313707 | 20.49 |
| 143 | Multiple myeloma and malignant plasma cell neoplasms (controls excluding all cancers) | FING00000843 | 20.46 |
| 144 | Risk taking | Mental health | UKBB00000759 | 20.39 |
| 145 | FKBP7 levels | GCST90469245 | 20.37 |
| 146 | Secondary hypothyroidism (PheCode 244.1) | GCST90475649 | 20.33 |
| 147 | MYCT1 levels | GCST90618046 | 20.31 |
| 148 | CD22/FCRL1 ratio | GCST90313757 | 20.30 |
| 149 | Bread type - Wholemeal or wholegrain | Diet | UKBB00000107 | 20.26 |
| 150 | 3,5-dichloro-2,6-dihydroxybenzoic acid levels | GCST90200252 | 20.25 |
| 151 | CD27 levels | GCST90468615 | 20.23 |
| 152 | ATP5IF1/LYN ratio | GCST90313389 | 20.23 |
| 153 | Number of vehicles in household | Household | UKBB00000543 | 19.99 |
| 154 | Treatment or medication use - insulin product (UKB data field 20003_1140883066) | GCST90042226 | 19.98 |
| 155 | Benign neoplasm of other and unspecified endocrine glands | FING00000159 | 19.98 |
| 156 | Depression | FING00000398 | 19.93 |
| 157 | C9 Carnitine levels in chronic kidney disease | GCST90257682 | 19.89 |
| 158 | ZNF830 levels | GCST90471102 | 19.79 |
| 159 | CD79B/FCRL1 ratio | GCST90313899 | 19.79 |
| 160 | Lymphoid neoplasms | GCST90624743 | 19.68 |
| 161 | Diacylglycerol_33:1_[M+H-H2O]1+ levels | GCST90060173 | 19.64 |
| 162 | MCTS1 levels | GCST90469874 | 19.49 |
| 163 | Leisure/social activities - Other group activity | Social support | UKBB00000400 | 19.31 |
| 164 | IBD (strict) with PSC | FING00000657 | 19.29 |
| 165 | Impacted cerumen (PheCode 380.4) | GCST90475901 | 19.29 |
| 166 | Hypercalcemia (PheCode 275.6) | GCST90475748 | 19.29 |
| 167 | EFNA4/VWC2 ratio | GCST90314607 | 19.20 |
| 168 | Lymphoid leukaemia (controls excluding all cancers) | FING00000741 | 19.19 |
| 169 | wg rh intensity-contrast lingual | GCST90003839 | 19.13 |
| 170 | Wears glasses or contact lenses | Eyesight | UKBB00000907 | 19.11 |
| 171 | Left ventricular end systole anterolateral wall thickness | GCST90278511 | 19.03 |
| 172 | CD22/FOLR2 ratio | GCST90313758 | 19.00 |
| 173 | Seropositive rheumatoid arthritis, wide | FING00001298 | 18.98 |
| 174 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475444 | 18.96 |
| 175 | FCGR2A levels | GCST90469200 | 18.91 |
| 176 | Fracture of radius and ulna (PheCode 803.2) | GCST90476280 | 18.90 |
| 177 | TNFRSF13C/TNFSF13B ratio | GCST90315934 | 18.89 |
| 178 | LY96 levels | GCST90469823 | 18.87 |
| 179 | Plasma argininate* levels in chronic kidney disease | GCST90264826 | 18.85 |
| 180 | CD27/TGFBR2 ratio | GCST90313776 | 18.80 |
| 181 | Number of days/week walked 10+ minutes | Physical activity | UKBB00000535 | 18.77 |
| 182 | CD209/CLEC14A ratio | GCST90313749 | 18.71 |
| 183 | Varicose veins of lower extremity, symptomtic (PheCode 454.11) | GCST90476014 | 18.62 |
| 184 | T1 FreeSurfer DKT rh insula area | GCST90384317 | 18.53 |
| 185 | CD27/NBL1 ratio | GCST90313774 | 18.49 |
| 186 | PGR levels | GCST90470223 | 18.47 |
| 187 | NUBP1 levels | GCST90470100 | 18.43 |
| 188 | Qualifications - None of the above | Education | UKBB00000729 | 18.42 |
| 189 | Percentage of FA2G1 in total neutral plasma glycans (GPn) (GP61) | GCST90668505 | 18.14 |
| 190 | ADAM23 levels | GCST90240922 | 18.06 |
| 191 | CD48 levels | GCST90425676 | 18.01 |
| 192 | Qualifications - O levels/GCSEs or equivalent | Education | UKBB00000731 | 18.00 |
| 193 | Irritable bowel syndrome | GCST90016564 | 17.98 |
| 194 | SSC-A on plasmacytoid Dendritic Cell | GCST90002072 | 17.95 |
| 195 | GZMA/IL12A_IL12B ratio | GCST90315009 | 17.89 |
| 196 | DTI TBSS L2 Sagittal stratum L | GCST90384507 | 17.87 |
| 197 | Seminoma of testis, excluding all cancers (controls excluding all cancers) | FING00001289 | 17.86 |
| 198 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475448 | 17.82 |
| 199 | CRTAP levels | GCST90468872 | 17.79 |
| 200 | FCRL5/ICAM3 ratio | GCST90314802 | 17.72 |
| 201 | IL2RA levels | GCST90469585 | 17.69 |
| 202 | Ceramide (d16:1/22:0) levels | GCST90024026 | 17.61 |
| 203 | Strenuous sports or other exercises | GCST006100 | 17.61 |
| 204 | ThalamNuclei rh volume MGN | GCST90002737 | 17.45 |
| 205 | FCRL5 levels | GCST90469208 | 17.27 |
| 206 | Diseases of middle ear and mastoid | FING00000427 | 17.18 |
| 207 | Multiple sclerosis | GCST90475833 | 17.07 |
| 208 | Operation code - wisdom teeth surgery | Operations | UKBB00000569 | 17.03 |
| 209 | lymphocyte (absolute count, mean, inv-norm transformed) | GCST90475426 | 16.99 |
| 210 | EDA2R levels | GCST90469067 | 16.97 |
| 211 | Right ventricular ejection fraction | GCST90134591 | 16.92 |
| 212 | Rheumatoid arthritis | GCST000679 | 16.91 |
| 213 | Plasma succinylcarnitine (C4-DC) levels in chronic kidney disease | GCST90265998 | 16.89 |
| 214 | CA1/CA3 ratio | GCST90313572 | 16.88 |
| 215 | Bread type - White | Diet | UKBB00000106 | 16.87 |
| 216 | Mother's age | Family history | UKBB00000484 | 16.74 |
| 217 | Bifidobacterium catenulatum abundance in stool | GCST90032224 | 16.73 |
| 218 | 5alpha-androstan-3alpha,17beta-diol monosulfate (1) levels | GCST90199858 | 16.70 |
| 219 | Influenza and pneumonia | FING00000679 | 16.69 |
| 220 | Experiencing mood swings | GCST006944 | 16.60 |
| 221 | Ulcerative colitis | GCST004133 | 16.57 |
| 222 | CALCOCO1/CRACR2A ratio | GCST90313598 | 16.50 |
| 223 | lymphocyte (absolute count, minimum, inv-norm transformed) | GCST90475429 | 16.45 |
| 224 | Broad bean liking | GCST90094711 | 16.43 |
| 225 | Age completed full time education | Education | UKBB00000013 | 16.41 |
| 226 | Triacylglycerol_50:2_[M+NH4]1+ levels | GCST90060473 | 16.38 |
| 227 | T1 CAT volume L LeftAccumbens | GCST90384108 | 16.35 |
| 228 | PIKFYVE levels | GCST90470235 | 16.32 |
| 229 | Osteoarthrosis (PheCode 740) | GCST90476253 | 16.30 |
| 230 | Red meat liking | GCST90094819 | 16.24 |
| 231 | AFP levels | GCST90468250 | 16.17 |
| 232 | HNRNPK/USP8 ratio | GCST90315070 | 16.15 |
| 233 | Rheumatoid arthritis | GCST90132223 | 16.05 |
| 234 | THY1 levels | GCST90470861 | 16.03 |
| 235 | wg rh intensity-contrast pericalcarine | GCST90003847 | 15.83 |
| 236 | C2 levels | GCST90468497 | 15.77 |
| 237 | Moderate-to-vigorous intensity physical activity during leisure time | GCST90104341 | 15.70 |
| 238 | Cough on most days | Medical information | UKBB00000153 | 15.70 |
| 239 | Triacylglycerol_50:3_[M+NH4]1+ levels | GCST90060468 | 15.67 |
| 240 | TOP1 levels | GCST90470933 | 15.62 |
| 241 | X-11444 metabolite level | GCST90616545 | 15.52 |
| 242 | Mood [affective] disorders | FING00000836 | 15.52 |
| 243 | CD40/TNFRSF14 ratio | GCST90313830 | 15.47 |
| 244 | Principal component-derived dietary pattern 42 | GCST90133047 | 15.45 |
| 245 | CD101 levels | GCST90468596 | 15.43 |
| 246 | Cereal type - Other (e.g. Cornflakes, Frosties) | Diet | UKBB00000125 | 15.36 |
| 247 | Unspecified dementia | FING00001400 | 15.27 |
| 248 | Cardiorespiratory fitness (vo2 max) | GCST90093317 | 15.24 |
| 249 | CLPP/DECR1 ratio | GCST90314137 | 15.20 |
| 250 | Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80) | GCST90668758 | 15.20 |
| 251 | Psoriasis vulgaris | GCST90018687 | 15.13 |
| 252 | GHRL levels | GCST90469341 | 15.10 |
| 253 | Hereditary hemolytic anemias (PheCode 282) | GCST90475779 | 15.10 |
| 254 | Operative procedures - Closed reduction of fracture of bone and fixation using nail or screw | Summary Operations | UKBB00000575 | 15.02 |
| 255 | CALCOCO1/TBC1D5 ratio | GCST90313610 | 15.00 |
| 256 | LGALS4 levels | GCST90469762 | 14.95 |
| 257 | Treatment/medication code - ventolin 100micrograms inhaler | Medications | UKBB00000860 | 14.93 |
| 258 | ABL1/DNMBP ratio | GCST90313149 | 14.91 |
| 259 | CD27/DLL1 ratio | GCST90313771 | 14.90 |
| 260 | Qualifications - A levels/AS levels or equivalent | Education | UKBB00000727 | 14.88 |
| 261 | Lymphocyte count | GCST90025984 | 14.71 |
| 262 | DTI TBSS L3 Posterior thalamic radiation R | GCST90384552 | 14.66 |
| 263 | Triacylglycerol_52:2_[M+NH4]1+ levels | GCST90060511 | 14.64 |
| 264 | F-sauces liking (derived food-liking factor) | GCST90094831 | 14.63 |
| 265 | CRTAM/LY9 ratio | GCST90314278 | 14.63 |
| 266 | High myopia | GCST009962 | 14.61 |
| 267 | IDP dMRI TBSS FA Retrolenticular part of internal capsule L | GCST90003898 | 14.58 |
| 268 | CHIT1 levels | GCST90468744 | 14.53 |
| 269 | Methods of admission to hospital (recoded) - Elective admission: Booked | Summary Administration | UKBB00000461 | 14.53 |
| 270 | CD302/IL12A_IL12B ratio | GCST90313806 | 14.53 |
| 271 | T1 FreeSurfer aseg Right-Caudate | GCST90384162 | 14.48 |
| 272 | Left ventricular end systole inferoseptal wall thickness | GCST90278508 | 14.45 |
| 273 | SLAMF1 levels | GCST90470649 | 14.33 |
| 274 | CRTAM/ICAM3 ratio | GCST90314276 | 14.32 |
| 275 | Principal component-derived dietary pattern 8 | GCST90133013 | 14.29 |
| 276 | ADM levels | GCST90011996 | 14.29 |
| 277 | Thyrotoxicosis with diffuse goitre | FING00001361 | 14.27 |
| 278 | Ulcerative colitis (strict) with PSC | FING00001389 | 14.23 |
| 279 | BSG/IL12A_IL12B ratio | GCST90313532 | 14.23 |
| 280 | Triacylglycerol_51:2_[M+NH4]1+ levels | GCST90060497 | 14.19 |
| 281 | Treatment/medication code - levothyroxine sodium | Medications | UKBB00000849 | 14.18 |
| 282 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502396 | 14.18 |
| 283 | AIDA levels | GCST90468265 | 14.17 |
| 284 | Seropositive rheumatoid arthritis, strict definition | FING00001297 | 14.16 |
| 285 | FCER1A levels | GCST90469198 | 14.15 |
| 286 | Total protein levels | UKBB00000826 | 14.13 |
| 287 | Takes medication for Skin condition (ex. Eczema, Psoriasis)? | GCST90475275 | 14.10 |
| 288 | Lymphocyte count | GCST90018742 | 14.07 |
| 289 | Types of physical activity in last 4 weeks - Walking for pleasure (not as a means of transport) | Physical activity | UKBB00000875 | 14.05 |
| 290 | wg lh intensity-contrast caudalmiddlefrontal | GCST90003795 | 13.96 |
| 291 | Total protein levels | GCST90018756 | 13.95 |
| 292 | Left ventricular end systole inferolateral wall thickness | GCST90278510 | 13.89 |
| 293 | POMC levels | GCST90470284 | 13.85 |
| 294 | CD74 levels | GCST90468647 | 13.85 |
| 295 | Degenerative skin conditions and other dermatoses (PheCode 702) | GCST90476202 | 13.80 |
| 296 | KDM3A levels | GCST90469671 | 13.75 |
| 297 | Triacylglycerol_53:2_[M+NH4]1+ levels | GCST90060531 | 13.70 |
| 298 | Volume of right cortico-amygdaloid transition area | GCST90475018 | 13.70 |
| 299 | Bread type: White (UKB data field 1448_1) | GCST90132964 | 13.69 |
| 300 | CLEC4G levels | GCST90468774 | 13.66 |
| 301 | Osteoarthrosis NOS (PheCode 740.9) | GCST90476256 | 13.65 |
| 302 | Prescriptions - levothyroxine | thyroid hormone | UKBB00000687 | 13.60 |
| 303 | Prescriptions - thyroid hormone | hormone | UKBB00000705 | 13.60 |
| 304 | Other and unspecified tonsillitis | FING00000954 | 13.55 |
| 305 | Total protein levels | GCST90468105 | 13.54 |
| 306 | ST13 levels | GCST90470751 | 13.54 |
| 307 | Bread type: White vs wholemeal/wholegrain and brown (UKB data field 1448) | GCST90132967 | 13.52 |
| 308 | FOLR2 levels | GCST90469260 | 13.52 |
| 309 | LRRC37A2 levels | GCST90469802 | 13.48 |
| 310 | ARTN levels | GCST90468372 | 13.41 |
| 311 | aparc-Desikan lh thickness paracentral | GCST90003461 | 13.38 |
| 312 | Nonspecific chest pain | circulatory system | UKBB00000527 | 13.38 |
| 313 | Occupation and workplace environment (confirmatory factor analysis Factor 5) | GCST90309340 | 13.37 |
| 314 | CD79B/CKAP4 ratio | GCST90313898 | 13.36 |
| 315 | Volume of right basal nucleus | GCST90475012 | 13.34 |
| 316 | CD27/CD79B ratio | GCST90313770 | 13.28 |
| 317 | Percentage of FA2G1 in total neutral plasma glycans (GPn) (GP61) | GCST90668739 | 13.28 |
| 318 | EIF3J levels | GCST90241122 | 13.27 |
| 319 | ERBB4/F3 ratio | GCST90314690 | 13.25 |
| 320 | Neurofibromatosis, type 2 | FING00000867 | 13.24 |
| 321 | Disorders of orbit | FING00000449 | 13.21 |
| 322 | Thyrotoxicosis | FING00001360 | 13.20 |
| 323 | Aplastic anemia (PheCode 284) | GCST90475783 | 13.11 |
| 324 | Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044) | GCST90042535 | 13.09 |
| 325 | REG3A levels | GCST90470449 | 13.04 |
| 326 | Crisps liking | GCST90094747 | 13.00 |
| 327 | GFRA2/IL12A_IL12B ratio | GCST90314925 | 12.99 |
| 328 | Rheumatoid arthritis | FING00001267 | 12.96 |
| 329 | HippSubfield lh volume CA4-body | GCST90002683 | 12.93 |
| 330 | DTI TBSS FA Posterior thalamic radiation R | GCST90384408 | 12.89 |
| 331 | Principal component-derived dietary pattern 16 | GCST90133021 | 12.88 |
| 332 | Bell pepper liking | GCST90094703 | 12.88 |
| 333 | CALCOCO1/IRAG2 ratio | GCST90313604 | 12.86 |
| 334 | CA3/HMBS ratio | GCST90313584 | 12.85 |
| 335 | Physical activity (Relative amplitude) | GCST90061432 | 12.85 |
| 336 | lymphocyte (absolute count, maximum, inv-norm transformed) | GCST90475423 | 12.84 |
| 337 | Hypothyroidism, drug reimbursement | FING00000655 | 12.84 |
| 338 | wg rh intensity-contrast cuneus | GCST90003831 | 12.81 |
| 339 | TNFRSF14/TNFSF14 ratio | GCST90315936 | 12.78 |
| 340 | CEACAM8/MMP9 ratio | GCST90314002 | 12.76 |
| 341 | 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels | GCST90200075 | 12.70 |
| 342 | CDKN2D/TACC3 ratio | GCST90313992 | 12.69 |
| 343 | Beetroot liking | GCST90094702 | 12.67 |
| 344 | Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), excluding all cancers (controls excluding all cancers) | FING00000846 | 12.67 |
| 345 | LILRB2 levels | GCST90469777 | 12.62 |
| 346 | Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41) | GCST90668485 | 12.59 |
| 347 | Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers) | FING00000756 | 12.58 |
| 348 | DEFA1_DEFA1B/LCN2 ratio | GCST90314454 | 12.50 |
| 349 | Alcohol drinker status - Current | Alcohol | UKBB00000021 | 12.46 |
| 350 | Mood swings | Mental health | UKBB00000482 | 12.45 |
| 351 | B2M levels | GCST90468409 | 12.43 |
| 352 | Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditions | UKBB00000518 | 12.40 |
| 353 | Fed-up feelings | Mental health | UKBB00000242 | 12.40 |
| 354 | Physical activity (Total log acceleration 10pm-12am) | GCST90061420 | 12.39 |
| 355 | Cereal type: Other (e.g. Cornflakes, Frosties) (UKB data field 1468_5) | GCST90132973 | 12.36 |
| 356 | TYRP1 levels | GCST90470998 | 12.35 |
| 357 | EPHB6/VWC2 ratio | GCST90314683 | 12.32 |
| 358 | Number of incorrect matches in round | Pairs matching | UKBB00000538 | 12.31 |
| 359 | Diacylglycerol_34:0_[M+H-H2O]1+ levels | GCST90060181 | 12.23 |
| 360 | Non-seminoma of testis, excluding all cancers (controls excluding all cancers) | FING00000874 | 12.18 |
| 361 | How are people in household related to participant - Husband, wife or partner | Household | UKBB00000330 | 12.09 |
| 362 | SFTPA1 levels | GCST90470612 | 12.08 |
| 363 | CDKN1A/TACC3 ratio | GCST90313975 | 12.07 |
| 364 | Active to sedentary transition probability | GCST90061429 | 12.06 |
| 365 | CD38/IL12A_IL12B ratio | GCST90313808 | 12.02 |
| 366 | SPINT1/SUSD2 ratio | GCST90315878 | 11.98 |
| 367 | Ceramide (d18:2/22:0) levels | GCST90024682 | 11.94 |
| 368 | ELOA/POLR2F ratio | GCST90314643 | 11.93 |
| 369 | PDCD1/TNFRSF9 ratio | GCST90315611 | 11.92 |
| 370 | Polyglandular dysfunction | FING00001186 | 11.87 |
| 371 | Corneal edema (PheCode 364.2) | GCST90475862 | 11.86 |
| 372 | Skin and soft tissue infections | GCST90013411 | 11.86 |
| 373 | SNX2 levels | GCST90470701 | 11.85 |
| 374 | Job involves mainly walking or standing | Employment | UKBB00000384 | 11.82 |
| 375 | ADH4/SCLY ratio | GCST90313195 | 11.82 |
| 376 | Types of physical activity in last 4 weeks - Other exercises (eg: swimming, cycling, keep fit, bowling) | Physical activity | UKBB00000873 | 11.77 |
| 377 | HippSubfield rh volume subiculum-body | GCST90002691 | 11.77 |
| 378 | IDP T1 FAST ROIs V cerebellum X | GCST90002588 | 11.74 |
| 379 | C1R levels | GCST90468493 | 11.74 |
| 380 | Osteoarthritis, localized (PheCode 740.1) | GCST90476254 | 11.71 |
| 381 | Volume of right accessory basal nucleus | GCST90475006 | 11.70 |
| 382 | Thyroid problems | GCST90475276 | 11.69 |
| 383 | Triacylglycerol_50:4_[M+NH4]1+ levels | GCST90060466 | 11.68 |
| 384 | Spherical power (left) | Autorefraction | UKBB00000790 | 11.61 |
| 385 | Allergy/adverse effect of penicillin | injuries & poisonings | UKBB00000028 | 11.59 |
| 386 | F-fruit liking (derived food-liking factor) | GCST90094767 | 11.52 |
| 387 | Spherical power (right) | Autorefraction | UKBB00000791 | 11.49 |
| 388 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60) | GCST90320623 | 11.48 |
| 389 | Use of disulfiram, acamprosate or naltrexone | FING00001410 | 11.48 |
| 390 | IPCEF1/TBCC ratio | GCST90315188 | 11.46 |
| 391 | SEPTIN8 levels | GCST90470578 | 11.42 |
| 392 | Illness, injury, bereavement, stress in last 2 years - Financial difficulties | Mental health | UKBB00000338 | 11.42 |
| 393 | LGALS8/SOD2 ratio | GCST90315320 | 11.42 |
| 394 | Types of physical activity in last 4 weeks - None of the above | Physical activity | UKBB00000872 | 11.31 |
| 395 | Time spent driving | Physical activity | UKBB00000818 | 11.25 |
| 396 | Salty food liking | GCST90094828 | 11.22 |
| 397 | QPCT levels | GCST90470401 | 11.21 |
| 398 | SNX15 levels | GCST90470699 | 11.20 |
| 399 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 11.18 |
| 400 | Hypothyroidism | GCST90468138 | 11.17 |
| 401 | Handedness (confirmatory factor analysis Factor 36) | GCST90309370 | 11.12 |
| 402 | MAPRE3 levels | GCST90469859 | 11.11 |
| 403 | Thyroid peroxidase antibody positivity in pregnancy | GCST90435202 | 11.09 |
| 404 | Pure hyperglyceridaemia | FING00001231 | 11.09 |
| 405 | RCC1 levels | GCST90470443 | 11.05 |
| 406 | REST UKBBICA NODEamps25 0003 | GCST90385486 | 11.04 |
| 407 | NME3 levels | GCST90470055 | 11.04 |
| 408 | Tyrosine levels | GCST90200427 | 11.03 |
| 409 | Right-hemisphere somatomotor network to pallidum white-matter structural connectivity | GCST90302797 | 11.02 |
| 410 | Eosinophill count | Blood count | UKBB00000206 | 11.01 |
| 411 | Diseases of white blood cells (PheCode 288) | GCST90475812 | 11.01 |
| 412 | ADD1 levels | GCST90468233 | 10.95 |
| 413 | Congestive heart failure; nonhypertensive (PheCode 428) | GCST90475981 | 10.94 |
| 414 | Eosinophill percentage | Blood count | UKBB00000207 | 10.93 |
| 415 | PAM levels | GCST90470156 | 10.92 |
| 416 | Mean sphered cell volume (UKB data field 30270) | GCST90468089 | 10.92 |
| 417 | T1 CAT volume L LeftPutamen | GCST90384100 | 10.88 |
| 418 | CD40/IGSF8 ratio | GCST90313815 | 10.88 |
| 419 | CD20 on IgD- CD27- B cell | GCST90001754 | 10.87 |
| 420 | Ceramide (d17:1/24:0) levels | GCST90024033 | 10.87 |
| 421 | X-21467 levels | GCST90200594 | 10.84 |
| 422 | Cereal type - Oat cereal (e.g. Ready Brek, porridge) | Diet | UKBB00000124 | 10.84 |
| 423 | Right ventricular ejection fraction (MTAG) | GCST90134595 | 10.84 |
| 424 | IL12A_IL12B/LAG3 ratio | GCST90315147 | 10.83 |
| 425 | ARL13B levels | GCST90468363 | 10.82 |
| 426 | Blood cell traits latent factor 12 (red cell) | GCST90559254 | 10.82 |
| 427 | DTI TBSS L1 Cingulum cingulate gyrus L | GCST90384463 | 10.80 |
| 428 | NOTCH1/SEMA7A ratio | GCST90315545 | 10.79 |
| 429 | CFHR2 levels | GCST90468726 | 10.76 |
| 430 | Graves' disease | GCST90018627 | 10.75 |
| 431 | Carcinoma in situ of breast, intraductal (controls excluding all cancers) | FING00000240 | 10.75 |
| 432 | Lamb liking | GCST90094790 | 10.74 |
| 433 | Pain in joint (PheCode 745) | GCST90476262 | 10.74 |
| 434 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476347 | 10.70 |
| 435 | Right-hemisphere salience/ventral attention network to thalamus white-matter structural connectivity | GCST90302817 | 10.70 |
| 436 | RAP1A levels | GCST90470425 | 10.69 |
| 437 | Skin color (cheek, ITA value) | GCST90502780 | 10.69 |
| 438 | Thyroid peroxidase antibody levels in pregnancy | GCST90435201 | 10.68 |
| 439 | Principal component-derived dietary pattern 28 | GCST90133033 | 10.68 |
| 440 | Appendectomy | FING00000104 | 10.67 |
| 441 | CILP levels | GCST90468754 | 10.66 |
| 442 | CD79B levels | GCST90468648 | 10.65 |
| 443 | Salami liking | GCST90094825 | 10.62 |
| 444 | DTI autoptx FA ilf r tract | GCST90385127 | 10.61 |
| 445 | T1 CAT volume R TemporalFusiformCortexposteriordivision | GCST90384075 | 10.59 |
| 446 | PECAM1/SOD2 ratio | GCST90315647 | 10.57 |
| 447 | MAMDC4 levels | GCST90469842 | 10.56 |
| 448 | Psoas tendinitis | FING00001221 | 10.54 |
| 449 | Transient global amnesia | FING00001374 | 10.53 |
| 450 | Types of transport used (excluding work) - Public transport | Physical activity | UKBB00000878 | 10.51 |
| 451 | ADGRE2 levels | GCST90468237 | 10.50 |
| 452 | Sphingomyelin_33:1_[M+H]1+ levels | GCST90060229 | 10.48 |
| 453 | FOXO1/MAP4K5 ratio | GCST90314872 | 10.42 |
| 454 | PDGFRB levels | GCST90470192 | 10.37 |
| 455 | Lamb or mutton consumption (UKB data field 1379) | GCST90132998 | 10.37 |
| 456 | Eosinophil count | GCST90025987 | 10.34 |
| 457 | BA-exvivo rh area BA45 | GCST90003229 | 10.33 |
| 458 | Triacylglycerol_52:3_[M+NH4]1+ levels | GCST90060509 | 10.32 |
| 459 | Liver liking | GCST90094794 | 10.32 |
| 460 | Thyroid cancer (PheCode 193) | GCST90475600 | 10.32 |
| 461 | CCL17/PDGFB ratio | GCST90313688 | 10.31 |
| 462 | Osteochondrodysplasia with defects of growth of tubular bones and spine | FING00000910 | 10.27 |
| 463 | IL12A or IL12B levels | GCST90469548 | 10.25 |
| 464 | PTPN1/WWP2 ratio | GCST90315746 | 10.25 |
| 465 | 1,5-anhydroglucitol (1,5-ag) levels | GCST90243529 | 10.24 |
| 466 | Recent inability to stop or control worrying | Anxiety | UKBB00000742 | 10.23 |
| 467 | Syncope and collapse | symptoms | UKBB00000801 | 10.20 |
| 468 | Biological Mother: Coronary Artery / Coronary Heart Disease | GCST90475488 | 10.16 |
| 469 | Types of physical activity in last 4 weeks - Heavy DIY (eg: weeding, lawn mowing, carpentry, digging) | Physical activity | UKBB00000870 | 10.15 |
| 470 | CD84/TREML2 ratio | GCST90313919 | 10.14 |
| 471 | Duration walking for pleasure | Physical activity | UKBB00000203 | 10.14 |
| 472 | TNFRSF11A levels | GCST90277644 | 10.14 |
| 473 | Educational attainment | GCST002598 | 10.13 |
| 474 | C1QTNF1/COL18A1 ratio | GCST90313551 | 10.12 |
| 475 | Lysoalkylphosphatidylcholine (O-24:0) levels | GCST90025436 | 10.11 |
| 476 | FAS levels | GCST90469192 | 10.10 |
| 477 | Schizophrenia or delusion (more control exclusions) | FING00001278 | 10.08 |
| 478 | Allergic conjunctivitis | FING00000067 | 10.08 |
| 479 | Right-hemisphere somatomotor network to amygdala white-matter structural connectivity | GCST90302799 | 10.06 |
| 480 | S100P levels | GCST90470520 | 10.02 |
| 481 | IDP T1 FAST ROIs R cerebellum V | GCST90002565 | 10.01 |
| 482 | Seborrheic keratosis (PheCode 702.2) | GCST90476206 | 10.00 |
| 483 | Takes medication for Thyroid problems? | GCST90475277 | 9.97 |
| 484 | Mean reticulocyte volume | GCST90025975 | 9.97 |
| 485 | HAVCR2 levels | GCST90421515 | 9.96 |
| 486 | LSP1 levels | GCST90469811 | 9.94 |
| 487 | Cervicobrachial syndrome | FING00000266 | 9.91 |
| 488 | PRTG levels | GCST90470347 | 9.89 |
| 489 | IL22 levels | GCST90469582 | 9.88 |
| 490 | Current employment status - In paid employment or self-employed | Employment | UKBB00000158 | 9.86 |
| 491 | Triacylglycerol_52:1_[M+NH4]1+ levels | GCST90060515 | 9.82 |
| 492 | Spinal stenosis | musculoskeletal | UKBB00000792 | 9.80 |
| 493 | Other diseases of upper respiratory tract | FING00001012 | 9.77 |
| 494 | PFKM levels | GCST90618802 | 9.77 |
| 495 | Omega-3 fatty acid levels | GCST90502422 | 9.75 |
| 496 | Wears glasses or contact lenses (UKB data field 2207) | GCST90042875 | 9.74 |
| 497 | Beef/steak liking | GCST90094700 | 9.74 |
| 498 | TNFRSF9 levels | GCST90470916 | 9.72 |
| 499 | Operation code - tonsillectomy +/- adenoids | Operations | UKBB00000567 | 9.72 |
| 500 | CD5/TNFRSF9 ratio | GCST90313862 | 9.72 |
| 501 | Soft tissue disorders | FING00001316 | 9.68 |
| 502 | CXCL11 levels | GCST90274781 | 9.65 |
| 503 | aparc-DKTatlas lh thickness paracentral | GCST90003555 | 9.65 |
| 504 | Autoimmune diseases | FING00000131 | 9.64 |
| 505 | T1 CAT volume R RightAccumbens | GCST90384109 | 9.64 |
| 506 | Strawberries liking | GCST90094849 | 9.61 |
| 507 | Heart failure with reduced EF [Systolic or combined heart failure] (PheCode 428.3) | GCST90475983 | 9.61 |
| 508 | Obstructive sleep apnea (PheCode 327.32) | GCST90475825 | 9.59 |
| 509 | Left-hemisphere limbic network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302732 | 9.59 |
| 510 | CNTNAP4 levels | GCST90468809 | 9.57 |
| 511 | FAM151A levels | GCST90242450 | 9.57 |
| 512 | Internal derangement of knee | injuries & poisonings | UKBB00000368 | 9.56 |
| 513 | IDP dMRI TBSS FA Posterior thalamic radiation L | GCST90003906 | 9.55 |
| 514 | Age when finished full-time education (standard GWA) | GCST90267280 | 9.54 |
| 515 | SEMA4C levels | GCST90470572 | 9.54 |
| 516 | Carnitine levels | GCST90199621 | 9.54 |
| 517 | T1 FreeSurfer aseg Right-Putamen | GCST90384163 | 9.51 |
| 518 | Psoriasis (PheCode 696.4) | GCST90476187 | 9.51 |
| 519 | Use of dietary supplements (confirmatory factor analysis Factor 13) | GCST90309347 | 9.50 |
| 520 | NFATC3 levels | GCST90470034 | 9.50 |
| 521 | TCN2 levels | GCST90470820 | 9.48 |
| 522 | Eosinophil percentage of white cells | GCST90002382 | 9.47 |
| 523 | Psoriasis vulgaris (PheCode 696.41) | GCST90476190 | 9.44 |
| 524 | Mosaic chromosomal alteration of the X chromosome | GCST90165287 | 9.43 |
| 525 | ADGRE5/VCAM1 ratio | GCST90313184 | 9.42 |
| 526 | aseg lh intensity Cerebellum-Cortex | GCST90003767 | 9.41 |
| 527 | Congenital lactase deficiency | FING00000329 | 9.39 |
| 528 | TNFRSF8/TNFRSF9 ratio | GCST90315940 | 9.38 |
| 529 | Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80) | GCST90668524 | 9.36 |
| 530 | LYN/TACC3 ratio | GCST90315350 | 9.35 |
| 531 | Mean sphered cell volume | Blood count | UKBB00000452 | 9.33 |
| 532 | Spleen volume | GCST90016667 | 9.33 |
| 533 | SNAP25 levels | GCST90422083 | 9.33 |
| 534 | Eustachian tube disorders (PheCode 381.2) | GCST90475904 | 9.32 |
| 535 | Ever worried more than most people would in similar situation | Anxiety | UKBB00000227 | 9.30 |
| 536 | Triacylglycerol_48:3_[M+NH4]1+ levels | GCST90060418 | 9.29 |
| 537 | Eosinophil count | GCST90002381 | 9.27 |
| 538 | RTBDN levels | GCST90470505 | 9.27 |
| 539 | CD160/NCR1 ratio | GCST90313732 | 9.25 |
| 540 | EZR levels | GCST90469162 | 9.24 |
| 541 | Drinks usually with meals in current drinkers (yes and it varies vs no) (UKB data field 1618) | GCST90132925 | 9.22 |
| 542 | CTSC levels | GCST90468909 | 9.22 |
| 543 | Triglyceride levels in very large HDL | GCST90132636 | 9.18 |
| 544 | Subjective well-being | GCST90104897 | 9.17 |
| 545 | CHI3L1/PRSS8 ratio | GCST90314044 | 9.16 |
| 546 | Substance use, excluding alcohol | FING00001342 | 9.15 |
| 547 | MS-disease / Multiple Sclerosis | FING00000839 | 9.14 |
| 548 | C1QL2 levels | GCST90468487 | 9.14 |
| 549 | Omega-3 fatty acids to total fatty acids percentage | GCST90502448 | 9.13 |
| 550 | CDHR1 levels | GCST90468678 | 9.12 |
| 551 | Left ventricular end diastole inferoseptal wall thickness | GCST90278514 | 9.11 |
| 552 | ERP29 levels | GCST90088843 | 9.10 |
| 553 | Principal component-derived dietary pattern 9 | GCST90133014 | 9.10 |
| 554 | Graves disease, strict definition | FING00000592 | 9.10 |
| 555 | Hypothyroidism, strict autoimmune | FING00000656 | 9.09 |
| 556 | CCL5/SELP ratio | GCST90313705 | 9.09 |
| 557 | Repeated disturbing thoughts of stressful experience in past month | Traumatic events | UKBB00000750 | 9.08 |
| 558 | Aniseed liking | GCST90094689 | 9.07 |
| 559 | PLXNB2 levels | GCST90470266 | 9.07 |
| 560 | CNTNAP2 levels | GCST90468808 | 9.02 |
| 561 | Comfortable retirement (confirmatory factor analysis Factor 29) | GCST90309363 | 9.02 |
| 562 | ANPEP/CXADR ratio | GCST90313272 | 8.97 |
| 563 | Eosinophill percentage (UKB data field 30210) | GCST90468069 | 8.97 |
| 564 | Poisoning by antibiotics | injuries & poisonings | UKBB00000653 | 8.97 |
| 565 | EFNA4/TNFRSF9 ratio | GCST90314606 | 8.96 |
| 566 | CABP2 levels | GCST90468519 | 8.93 |
| 567 | HippSubfield rh volume presubiculum-head | GCST90002695 | 8.93 |
| 568 | rfMRI connectivity (ICA100 edge 495) | GCST90005348 | 8.92 |
| 569 | IDP T1 FAST ROIs L subcallosal cortex | GCST90002503 | 8.90 |
| 570 | Ratio of bis-allylic bonds to double bonds in lipids | GCST90132744 | 8.89 |
| 571 | ICAM3/LY9 ratio | GCST90315121 | 8.89 |
| 572 | SKAP1 levels | GCST90470645 | 8.88 |
| 573 | Dizziness and giddiness (Light-headedness and vertigo) (PheCode 386.9) | GCST90475908 | 8.87 |
| 574 | Diseases of external ear | FING00000424 | 8.86 |
| 575 | Gastroesophageal reflux disease | GCST90000514 | 8.86 |
| 576 | CCDC50 levels | GCST90468561 | 8.85 |
| 577 | PDGFA/USP8 ratio | GCST90315621 | 8.84 |
| 578 | Nerve, nerve root and plexus disorders | FING00000862 | 8.83 |
| 579 | POSTN levels | GCST90470288 | 8.81 |
| 580 | Chalazion | FING00000267 | 8.81 |
| 581 | Cereal type - Muesli | Diet | UKBB00000123 | 8.81 |
| 582 | Osteoarthrosis, localized, primary (PheCode 740.11) | GCST90476255 | 8.78 |
| 583 | MGAT2 levels | GCST90089560 | 8.78 |
| 584 | Asthma (adult onset) | GCST007799 | 8.78 |
| 585 | Hypothyroidism | GCST90319320 | 8.77 |
| 586 | Urine N1,N12-diacetylspermine levels in chronic kidney disease | GCST90265683 | 8.76 |
| 587 | AV-block | FING00000137 | 8.75 |
| 588 | Mineral and other dietary supplements - None of the above | Medication | UKBB00000474 | 8.74 |
| 589 | F-cooking flavour liking (derived food-liking factor) | GCST90094742 | 8.74 |
| 590 | CD164/CD99 ratio | GCST90313740 | 8.74 |
| 591 | wg rh intensity-contrast superiorfrontal | GCST90003854 | 8.73 |
| 592 | SEMA7A levels | GCST90470575 | 8.73 |
| 593 | Use of hypnotics and sedatives | FING00001411 | 8.73 |
| 594 | T1 CAT GM unnormalised volume | GCST90383982 | 8.72 |
| 595 | 1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels | GCST90199652 | 8.71 |
| 596 | All pneumoniae | FING00000065 | 8.71 |
| 597 | UCMA levels | GCST90243285 | 8.70 |
| 598 | Psoriatic arthropathies | FING00001225 | 8.69 |
| 599 | Triacylglycerol_51:3_[M+NH4]1+ levels | GCST90060494 | 8.68 |
| 600 | T1 CAT volume R RightThalamus | GCST90384097 | 8.68 |
| 601 | Social trust (aggregated) | GCST90319315 | 8.66 |
| 602 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 102) | GCST90320665 | 8.63 |
| 603 | CXCL5/PLXNA4 ratio | GCST90314351 | 8.63 |
| 604 | Psoriasis and related disorder (PheCode 696) | GCST90476186 | 8.61 |
| 605 | Cardiorespiratory fitness slope | GCST90093320 | 8.60 |
| 606 | Estradiol levels | GCST90012105 | 8.58 |
| 607 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T276 | ECGU000276 | 8.58 |
| 608 | Loneliness, isolation | Mental health | UKBB00000408 | 8.57 |
| 609 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T305 | ECGA000305 | 8.57 |
| 610 | HippSubfield rh volume CA1-body | GCST90002692 | 8.54 |
| 611 | ACY1/SCLY ratio | GCST90313165 | 8.54 |
| 612 | FOLH1 levels | GCST90425661 | 8.54 |
| 613 | Family relationship satisfaction | Mental health | UKBB00000238 | 8.53 |
| 614 | X-11787 levels | GCST90200465 | 8.53 |
| 615 | Postinflammatory pulmonary fibrosis (PheCode 502) | GCST90476032 | 8.52 |
| 616 | Participation in an health questionnaire (not invited vs invited) | GCST90012794 | 8.51 |
| 617 | VAMP5 levels | GCST90471024 | 8.51 |
| 618 | GOLM2/ITGA5 ratio | GCST90314951 | 8.50 |
| 619 | Chronic diseases of tonsils and adenoids | FING00000283 | 8.50 |
| 620 | Cereal type: Muesli (UKB data field 1468_4) | GCST90132972 | 8.48 |
| 621 | 4-androsten-3beta,17beta-diol disulfate 1 levels | GCST90243879 | 8.48 |
| 622 | Other hypothyroidism | Disorders of thyroid gland | UKBB00000611 | 8.48 |
| 623 | DTI TBSS FA Posterior thalamic radiation L | GCST90384409 | 8.46 |
| 624 | Hypothyroidism | GCST90204167 | 8.46 |
| 625 | CLEC4C levels | GCST90468772 | 8.45 |
| 626 | Ulcerative colitis | GCST90018713 | 8.44 |
| 627 | Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448) | GCST90132968 | 8.44 |
| 628 | CD244/CRTAM ratio | GCST90313763 | 8.42 |
| 629 | Erythematosquamous dermatosis (PheCode 690) | GCST90476170 | 8.42 |
| 630 | Tryptophan betaine levels | GCST90199819 | 8.39 |
| 631 | FGF21 levels | GCST90274788 | 8.38 |
| 632 | PADI2 levels | GCST90470142 | 8.38 |
| 633 | TDRKH/TST ratio | GCST90315913 | 8.35 |
| 634 | THBS2 levels | GCST90470854 | 8.34 |
| 635 | ATP5IF1/FXN ratio | GCST90313386 | 8.33 |
| 636 | Eosinophil count | GCST90002298 | 8.33 |
| 637 | Prescriptions - antispasmodic | UKBB00000666 | 8.32 |
| 638 | Medication use (glucocorticoids) | GCST90018780 | 8.32 |
| 639 | ZP3 levels | GCST90471105 | 8.29 |
| 640 | CSNK1D levels | GCST90468888 | 8.29 |
| 641 | Eosinophil percentage of white cells | GCST004600 | 8.28 |
| 642 | SLAMF7 levels | GCST90470651 | 8.27 |
| 643 | DCTN6/TDRKH ratio | GCST90314436 | 8.27 |
| 644 | Eosinophill count (UKB data field 30150) | GCST90468068 | 8.27 |
| 645 | Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35) | GCST90309369 | 8.24 |
| 646 | CD48/CRTAM ratio | GCST90313839 | 8.23 |
| 647 | GABBR2 levels | GCST90241230 | 8.22 |
| 648 | Bread type: Wholemeal or wholegrain (UKB data field 1448_3) | GCST90132966 | 8.22 |
| 649 | DAB2/FKBP1B ratio | GCST90314362 | 8.22 |
| 650 | Usual side of head for mobile phone use - Left | Electronic device use | UKBB00000889 | 8.21 |
| 651 | Phenylalanine levels | GCST90092936 | 8.20 |
| 652 | MGLL/MITD1 ratio | GCST90315436 | 8.20 |
| 653 | LGALS3BP levels | GCST90469760 | 8.20 |
| 654 | Number of non-cancer illnesses (standard GWA) | GCST90267290 | 8.19 |
| 655 | TNFSF14 levels | GCST90470922 | 8.18 |
| 656 | HippSubfield rh volume subiculum-head | GCST90002693 | 8.18 |
| 657 | Hypothyroidism NOS | endocrine/metabolic | UKBB00000336 | 8.17 |
| 658 | CCL3 levels | GCST90012055 | 8.17 |
| 659 | Reimbursement for rheumatic diseases | FING00001247 | 8.17 |
| 660 | ARHGAP30 levels | GCST90468354 | 8.17 |
| 661 | ECG, load | ECG during exercise | UKBB00000205 | 8.13 |
| 662 | Smoking status (standard GWA) | GCST90267302 | 8.13 |
| 663 | Diacylglycerol_34:3_[M+H-H2O]1+ levels | GCST90060177 | 8.11 |
| 664 | FABP1/SULT2A1 ratio | GCST90314755 | 8.11 |
| 665 | AXIN1/SRPK2 ratio | GCST90313417 | 8.09 |
| 666 | Autoimmune hyperthyroidism | FING00000134 | 8.08 |
| 667 | wg rh intensity-contrast lateraloccipital | GCST90003837 | 8.08 |
| 668 | Estradiol levels | GCST90020091 | 8.07 |
| 669 | Brussel sprout liking | GCST90094714 | 8.07 |
| 670 | CAPN3 levels | GCST90468538 | 8.04 |
| 671 | Eosinophil count | GCST004606 | 8.04 |
| 672 | Acceptance of an invitation to participate in a mental health questionnaire | GCST90012792 | 8.04 |
| 673 | Other systemic involvement of connective tissue (FG) | FING00001116 | 8.03 |
| 674 | Nephrotic syndrome | GCST90018664 | 8.01 |
| 675 | Seborrheic dermatitis (PheCode 690.1) | GCST90476171 | 8.01 |
| 676 | aparc-a2009s rh thickness G-temporal-middle | GCST90003714 | 8.01 |
| 677 | aseg rh volume Amygdala | GCST90002642 | 8.01 |
| 678 | Hypothyroidism | endocrine/metabolic | UKBB00000335 | 7.98 |
| 679 | DTI TBSS L3 Sagittal stratum L | GCST90384555 | 7.95 |
| 680 | IL12B levels | GCST90469549 | 7.94 |
| 681 | GZMA/LTA ratio | GCST90315012 | 7.94 |
| 682 | Respiratory disease (confirmatory factor analysis Factor 11) | GCST90309345 | 7.94 |
| 683 | Rubneribacter sp002159915 abundance in stool | GCST90032541 | 7.93 |
| 684 | Left ventricular end diastolic mass | GCST90268123 | 7.93 |
| 685 | CD22/CD79B ratio | GCST90313755 | 7.91 |
| 686 | Ventricular arrhythmia | GCST90018720 | 7.89 |
| 687 | SERPINE1/USP8 ratio | GCST90315835 | 7.89 |
| 688 | Light-intensity physical activity duration | GCST90061421 | 7.87 |
| 689 | Conditional arithmetic | Fluid intelligence / reasoning | UKBB00000145 | 7.86 |
| 690 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T284 | ECGU000284 | 7.85 |
| 691 | DRAXIN levels | GCST90469038 | 7.84 |
| 692 | Alcohol usually taken with meals (UKB data field 1618) | GCST90133004 | 7.84 |
| 693 | Cardiorespiratory fitness (vo2 max) | GCST90093316 | 7.83 |
| 694 | Age when finished full-time education (weighted GWA) | GCST90267281 | 7.80 |
| 695 | Mean spheric corpuscular volume | GCST90002397 | 7.80 |
| 696 | X-12063 levels | GCST90243687 | 7.77 |
| 697 | ADGRE5/SEMA7A ratio | GCST90313183 | 7.77 |
| 698 | Mean carotid IMT (intima-medial thickness) at 240 degrees | Carotid ultrasound | UKBB00000446 | 7.77 |
| 699 | Late-onset myasthenia gravis | GCST90432158 | 7.76 |
| 700 | CRYGD levels | GCST90468876 | 7.74 |
| 701 | aparc-a2009s lh volume S-circular-insula-sup | GCST90002973 | 7.73 |
| 702 | TNFRSF6B levels | GCST90470914 | 7.73 |
| 703 | Age hay fever, rhinitis or eczema diagnosed | Medical conditions | UKBB00000015 | 7.71 |
| 704 | Disorders of the thyroid gland | FING00000463 | 7.71 |
| 705 | Time to complete round | Pairs matching | UKBB00000822 | 7.70 |
| 706 | Skin sebum (glabella) | GCST90502797 | 7.70 |
| 707 | ATOX1/TMSB10 ratio | GCST90313377 | 7.69 |
| 708 | Cholesteryl ester (16:2) levels | GCST90024628 | 7.69 |
| 709 | PADI4 levels | GCST90470143 | 7.68 |
| 710 | Telomere length (principal component 1) | GCST90435144 | 7.66 |
| 711 | MANSC1/PODXL2 ratio | GCST90315371 | 7.66 |
| 712 | DTI TBSS L2 Posterior thalamic radiation R | GCST90384504 | 7.66 |
| 713 | MAP3K5/MAVS ratio | GCST90315379 | 7.64 |
| 714 | CD200/CLEC4G ratio | GCST90313746 | 7.64 |
| 715 | TNFRSF4/TNFRSF8 ratio | GCST90315938 | 7.64 |
| 716 | Cancer of urinary organs (incl. kidney and bladder) (PheCode 189) | GCST90475593 | 7.63 |
| 717 | Clonal hematopoiesis (large clone) | GCST90102621 | 7.62 |
| 718 | Urine 16a-hydroxy DHEA 3-sulfate levels in chronic kidney disease | GCST90264329 | 7.62 |
| 719 | IRAG2/TBC1D23 ratio | GCST90315191 | 7.60 |
| 720 | IDP T1 FAST ROIs L postcent gyrus | GCST90002483 | 7.59 |
| 721 | IFI30 levels | GCST90469509 | 7.58 |
| 722 | COL9A1 levels | GCST90468822 | 7.56 |
| 723 | DTI autoptx FA ifo r tract | GCST90385125 | 7.56 |
| 724 | LTA levels | GCST90469813 | 7.55 |
| 725 | DTI autoptx FA ptr l tract | GCST90385131 | 7.55 |
| 726 | BAG6/BMP6 ratio | GCST90313450 | 7.55 |
| 727 | CEP43/USP8 ratio | GCST90314022 | 7.53 |
| 728 | CEACAM8 levels | GCST90468698 | 7.53 |
| 729 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 7.51 |
| 730 | LCN2/PGLYRP1 ratio | GCST90315306 | 7.51 |
| 731 | AmygNuclei lh volume Central-nucleus | GCST90002652 | 7.50 |
| 732 | Minimum carotid IMT (intima-medial thickness) at 210 degrees | Carotid ultrasound | UKBB00000477 | 7.48 |
| 733 | Asthma | GCST010042 | 7.47 |
| 734 | T1 FreeSurfer a2009s rh S temporal sup volume | GCST90385110 | 7.47 |
| 735 | Physical activity (Total log acceleration 8am-10am) | GCST90061413 | 7.46 |
| 736 | Prescriptions - amlodipine | calcium channel blocker,dihydropyridine,anti-hypertensive | UKBB00000660 | 7.45 |
| 737 | GDI2 levels | GCST90088004 | 7.43 |
| 738 | HippSubfield rh volume CA4-body | GCST90002705 | 7.43 |
| 739 | Mean reticulocyte volume | Blood count | UKBB00000451 | 7.42 |
| 740 | Number of sexual partners in opposite-sex sexual behavior | GCST90026481 | 7.38 |
| 741 | PLXNB2/SEMA7A ratio | GCST90315692 | 7.38 |
| 742 | aseg rh intensity Cerebellum-Cortex | GCST90003781 | 7.37 |
| 743 | T1 FreeSurfer aseg Left-Caudate | GCST90384144 | 7.36 |
| 744 | HippSubfield lh volume GC-ML-DG-body | GCST90002681 | 7.35 |
| 745 | Usual side of head for mobile phone use - Right | Electronic device use | UKBB00000890 | 7.35 |
| 746 | CCS levels | GCST90468594 | 7.35 |
| 747 | FABP1 levels | GCST90469173 | 7.34 |
| 748 | Treatment/medication code - lansoprazole | Medications | UKBB00000848 | 7.34 |
| 749 | DNAJB2 levels | GCST90469013 | 7.34 |
| 750 | IDP dMRI TBSS L2 Posterior thalamic radiation L | GCST90004152 | 7.34 |
| 751 | Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia | GCST90624744 | 7.33 |
| 752 | Coffee type: Decaffeinated coffee (any type) (UKB data field 1508_1) | GCST90132974 | 7.32 |
| 753 | Early-onset myasthenia gravis | GCST90093465 | 7.31 |
| 754 | ATF6 levels | GCST90240816 | 7.31 |
| 755 | CD48/FCRL6 ratio | GCST90313840 | 7.30 |
| 756 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditions | UKBB00000101 | 7.30 |
| 757 | Non-cancer illness code, self-reported - asthma | Medical conditions | UKBB00000506 | 7.28 |
| 758 | rfMRI connectivity ICA-features 6 | GCST90006344 | 7.27 |
| 759 | Financial situation satisfaction | Mental health | UKBB00000249 | 7.27 |
| 760 | Methods of discharge from hospital (recoded) - Discharged on clinical advice/consent | Summary Administration | UKBB00000466 | 7.26 |
| 761 | Disorders of other endocrine glands | FING00000450 | 7.25 |
| 762 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 7.25 |
| 763 | LRIG3 levels | GCST90469795 | 7.23 |
| 764 | Androstenediol (3beta,17beta) disulfate (2) levels | GCST90199851 | 7.22 |
| 765 | CXCL10 levels | GCST90274780 | 7.22 |
| 766 | Soy sauce liking | GCST90094844 | 7.22 |
| 767 | Ulcerative rectosigmoiditis | FING00001394 | 7.21 |
| 768 | RASSF2 levels | GCST90470431 | 7.21 |
| 769 | Drive faster than motorway speed limit | Physical activity | UKBB00000194 | 7.20 |
| 770 | GALNT5 levels | GCST90469298 | 7.20 |
| 771 | Feeling lonely | GCST006942 | 7.20 |
| 772 | Cervical cancer | GCST90018597 | 7.20 |
| 773 | Suicide or other Intentional self-harm | FING00001345 | 7.20 |
| 774 | Birth year infant mortality rates | GCST90095047 | 7.19 |
| 775 | wg lh intensity-contrast superiorfrontal | GCST90003819 | 7.18 |
| 776 | Suppurative and unspecified otitis media | FING00001346 | 7.18 |
| 777 | CD27/FCRL5 ratio | GCST90313772 | 7.17 |
| 778 | Number of operations, self-reported | Operations | UKBB00000539 | 7.16 |
| 779 | Thyroid peroxidase antibody positivity with euthyroid in pregnancy | GCST90435203 | 7.16 |
| 780 | BIN1 levels | GCST90090757 | 7.16 |
| 781 | DTI autoptx FA ifo l tract | GCST90385124 | 7.13 |
| 782 | Ulcerative colitis (PheCode 555.2) | GCST90044155 | 7.13 |
| 783 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 7.13 |
| 784 | Red wine consumption (glasses per month) (UKB data field 1578, 4419) | GCST90132987 | 7.12 |
| 785 | Plasma glycocholenate sulfate* levels in chronic kidney disease | GCST90265291 | 7.10 |
| 786 | IDP T1 FAST ROIs L cerebellum X | GCST90002587 | 7.09 |
| 787 | VEGFB levels | GCST90471035 | 7.08 |
| 788 | Dissociative [conversion] disorders | FING00000468 | 7.08 |
| 789 | Cerebrospinal fluid 5-methylthioadenosine (MTA) levels | GCST90318216 | 7.08 |
| 790 | Left-hemisphere control network to caudate white-matter structural connectivity | GCST90302753 | 7.07 |
| 791 | DTI TBSS L2 Posterior thalamic radiation L | GCST90384505 | 7.07 |
| 792 | GFRA2 levels | GCST90469329 | 7.07 |
| 793 | Squamous cell carcinoma (PheCode 172.22) | GCST90475583 | 7.06 |
| 794 | Prescriptions - calcium channel blocker|dihydropyridine|anti-hypertensive | UKBB00000673 | 7.06 |
| 795 | Total Phosphatidylethanolamine levels | GCST90025207 | 7.05 |
| 796 | ARHGAP25/RNF41 ratio | GCST90313345 | 7.05 |
| 797 | EFNA4 levels | GCST90469081 | 7.05 |
| 798 | SIT1 levels | GCST90470644 | 7.05 |
| 799 | ADH4/CA5A ratio | GCST90313189 | 7.02 |
| 800 | Clonal haematopoiesis of indeterminate potential (TET2 mutation) | GCST90165281 | 7.02 |
| 801 | Sedentary behavior at work | GCST90104345 | 7.01 |
| 802 | KLRB1 levels | GCST90469709 | 7.00 |
| 803 | CHRDL1 levels | GCST90468750 | 6.99 |
| 804 | NPC2 levels | GCST90470068 | 6.98 |
| 805 | GALNT10/SEMA7A ratio | GCST90314915 | 6.97 |
| 806 | PPP1R2/USP8 ratio | GCST90315723 | 6.96 |
| 807 | Attendance/disability/mobility allowance - Disability living allowance | Other sociodemographic factors | UKBB00000058 | 6.95 |
| 808 | ENPP5 levels | GCST90469116 | 6.94 |
| 809 | wg lh intensity-contrast lingual | GCST90003804 | 6.94 |
| 810 | BAMBI levels | GCST90468420 | 6.93 |
| 811 | CRTAM levels | GCST90468871 | 6.90 |
| 812 | CD244 levels | GCST90274771 | 6.87 |
| 813 | TNF/TNFRSF1B ratio | GCST90315942 | 6.86 |
| 814 | Vitamin D levels | GCST005367 | 6.86 |
| 815 | ADGRE1 levels | GCST90468236 | 6.84 |
| 816 | Physical activity (Total log acceleration) | GCST90061408 | 6.83 |
| 817 | DKK3 levels | GCST90468998 | 6.83 |
| 818 | T1 FreeSurfer aseg Right-Pallidum | GCST90384164 | 6.83 |
| 819 | F-highly palatable foods liking (derived food-liking factor) | GCST90094785 | 6.83 |
| 820 | Anxiety disorders (more control exclusions) | FING00000098 | 6.82 |
| 821 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T283 | ECGU000283 | 6.82 |
| 822 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T229 | ECGU000229 | 6.81 |
| 823 | Educational attainment | GCST003496 | 6.78 |
| 824 | CLEC4G/NELL2 ratio | GCST90314122 | 6.78 |
| 825 | Blood cell traits latent factor 9 (white cell) | GCST90559251 | 6.77 |
| 826 | Crohn's disease | GCST004132 | 6.76 |
| 827 | Smoking status (weighted GWA) | GCST90267303 | 6.75 |
| 828 | CCL16 levels | GCST90468568 | 6.74 |
| 829 | Psoriasis | GCST90468147 | 6.74 |
| 830 | FABP1/LGALS4 ratio | GCST90314752 | 6.73 |
| 831 | NUDT5/TXNRD1 ratio | GCST90315582 | 6.72 |
| 832 | Emotionally unstable personality disorder | FING00000495 | 6.71 |
| 833 | T1 FreeSurfer a2009s rh S temporal sup area | GCST90384962 | 6.71 |
| 834 | Volume of right whole amygdala | GCST90475054 | 6.71 |
| 835 | Eosinophil percentage of granulocytes | GCST004617 | 6.70 |
| 836 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T275 | ECGU000275 | 6.70 |
| 837 | Mean reticulocyte volume (UKB data field 30260) | GCST90468088 | 6.70 |
| 838 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 6.70 |
| 839 | Psoriasis (vulgaris), strict definition | FING00001223 | 6.69 |
| 840 | Chicken liking | GCST90094732 | 6.68 |
| 841 | DNA methylation PhenoAge acceleration | GCST90014292 | 6.67 |
| 842 | CCL3 levels | GCST90468582 | 6.67 |
| 843 | Red cell distribution width variance | GCST90565705 | 6.67 |
| 844 | Burger liking | GCST90094715 | 6.67 |
| 845 | Acute upper respiratory infections | FING00000034 | 6.66 |
| 846 | Systemic connective tissue disorders | FING00001350 | 6.65 |
| 847 | Apples liking | GCST90094691 | 6.64 |
| 848 | ISEI occupational score | GCST90446160 | 6.64 |
| 849 | Other disorders of the musculoskeletal system and connective tissue | FING00001038 | 6.64 |
| 850 | CEACAM8/PGLYRP1 ratio | GCST90314003 | 6.63 |
| 851 | Congestive heart failure (CHF) NOS (PheCode 428.1) | GCST90475982 | 6.63 |
| 852 | Heart failure with preserved EF [Diastolic heart failure] (PheCode 428.4) | GCST90475984 | 6.62 |
| 853 | Mean corpuscular hemoglobin concentration | GCST90018745 | 6.61 |
| 854 | Diarrhoea and gastroenteritis of presumed infectious origin | FING00000420 | 6.60 |
| 855 | Triglycerides x depression interaction (2df test) | GCST90570679 | 6.60 |
| 856 | Asthma (childhood onset) | GCST007800 | 6.60 |
| 857 | IDP T1 FAST ROIs R postcent gyrus | GCST90002484 | 6.60 |
| 858 | aseg rh number HolesBeforeFixing | GCST90002647 | 6.60 |
| 859 | BA-exvivo rh area BA6 | GCST90003227 | 6.59 |
| 860 | Dementia due to Parkinson's disease (more control exclusions) | FING00000392 | 6.58 |
| 861 | Frequency of heavy DIY in last 4 weeks | Physical activity | UKBB00000263 | 6.58 |
| 862 | CD163/ICAM1 ratio | GCST90313735 | 6.57 |
| 863 | DIABLO/PDGFB ratio | GCST90314468 | 6.56 |
| 864 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T304 | ECGA000304 | 6.55 |
| 865 | Lymphocyte percentage of white cells | GCST90002389 | 6.55 |
| 866 | Hair colour (natural, before greying) - Dark brown | Sun exposure | UKBB00000297 | 6.54 |
| 867 | eosinophil (fraction, mean, inv-norm transformed) | GCST90475300 | 6.54 |
| 868 | IDP T1 FAST ROIs L cerebellum VI | GCST90002566 | 6.53 |
| 869 | Shortness of breath (PheCode 512.7) | GCST90476040 | 6.53 |
| 870 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditions | UKBB00000098 | 6.52 |
| 871 | F-strong flavour liking (derived food-liking factor) | GCST90094851 | 6.50 |
| 872 | CA1/HMBS ratio | GCST90313573 | 6.50 |
| 873 | Any mental disorder | FING00000100 | 6.50 |
| 874 | CD244/TREML2 ratio | GCST90313767 | 6.49 |
| 875 | Age at first sexual intercourse | GCST90000045 | 6.47 |
| 876 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T287 | ECGU000287 | 6.47 |
| 877 | rfMRI amplitudes (ICA100 node 27) | GCST90004615 | 6.47 |
| 878 | MGLL/STK4 ratio | GCST90315443 | 6.46 |
| 879 | ADM levels | GCST90468246 | 6.45 |
| 880 | CRTAM/VCAM1 ratio | GCST90314281 | 6.45 |
| 881 | PGLYRP1 levels | GCST90470219 | 6.44 |
| 882 | PTN levels | GCST90470374 | 6.44 |
| 883 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditions | UKBB00000100 | 6.44 |
| 884 | Non-cancer illness code, self-reported - diabetes | Medical conditions | UKBB00000508 | 6.43 |
| 885 | Mean reticulocyte volume | GCST90002396 | 6.42 |
| 886 | Ceramide (d17:1/22:0) levels | GCST90024032 | 6.42 |
| 887 | MMP1 levels | GCST90469919 | 6.42 |
| 888 | Sum eosinophil basophil counts | GCST004624 | 6.40 |
| 889 | Illness, injury, bereavement, stress in last 2 years - None of the above | Mental health | UKBB00000339 | 6.39 |
| 890 | Chronic obstructive pulmonary disease in current smokers | GCST90016593 | 6.37 |
| 891 | aparc-DKTatlas rh thickness lingual | GCST90003582 | 6.37 |
| 892 | PLAUR levels | GCST90012051 | 6.35 |
| 893 | Diseases of the digestive system | FING00000429 | 6.32 |
| 894 | Other and/or unspecified nontoxic goitre | FING00000958 | 6.32 |
| 895 | Second line medication for Crohn's disease | FING00001284 | 6.32 |
| 896 | Mid-point of the five least active hours of the day | GCST90061434 | 6.31 |
| 897 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T277 | ECGU000277 | 6.30 |
| 898 | CD20 on IgD- CD38- B cell | GCST90001755 | 6.30 |
| 899 | AK1 levels | GCST90468269 | 6.30 |
| 900 | Omega-6 fatty acid levels | GCST90502519 | 6.29 |
| 901 | Plasma X-26054 levels in chronic kidney disease | GCST90266858 | 6.27 |
| 902 | Lichen ruber planus, wide definition including periferal and oral lichen planus | FING00000722 | 6.27 |
| 903 | Autoimmune diseases excluding thyroid diseases | FING00000132 | 6.27 |
| 904 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 6.26 |
| 905 | LAIR2 levels | GCST90469729 | 6.26 |
| 906 | Insomnia (weighted GWA) | GCST90267287 | 6.24 |
| 907 | Ulcerative colitis (strict definition, require KELA, min 2 HDR) | FING00001388 | 6.23 |
| 908 | Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditions | UKBB00000513 | 6.22 |
| 909 | GZMB levels | GCST90469424 | 6.22 |
| 910 | Hair colour (natural, before greying): Dark brown (UKB data field 1747_4) | GCST90041839 | 6.21 |
| 911 | PDGFA/SPARC ratio | GCST90315620 | 6.21 |
| 912 | Meniscus derangement | FING00000807 | 6.21 |
| 913 | PPP2R2A levels | GCST90618122 | 6.21 |
| 914 | Uterine fibroids | GCST90468154 | 6.20 |
| 915 | RNASET2 levels | GCST90470481 | 6.18 |
| 916 | Insomnia (PheCode 327.4) | GCST90475826 | 6.18 |
| 917 | N-formylanthranilic acid levels | GCST90199960 | 6.17 |
| 918 | SULT2A1 levels | GCST90470782 | 6.17 |
| 919 | Frequency of tiredness / lethargy in last 2 weeks | Mental health | UKBB00000268 | 6.16 |
| 920 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 6.16 |
| 921 | ITGB1BP2/PTPN6 ratio | GCST90315218 | 6.15 |
| 922 | PPP1R2/TACC3 ratio | GCST90315719 | 6.15 |
| 923 | GDNF levels | GCST90274792 | 6.14 |
| 924 | neutrophil (fraction, mean, inv-norm transformed) | GCST90475538 | 6.14 |
| 925 | T1 FreeSurfer aseg Right-choroid-plexus | GCST90384170 | 6.13 |
| 926 | FCAMR levels | GCST90469196 | 6.13 |
| 927 | IDP dMRI ProbtrackX OD str l | GCST90004473 | 6.12 |
| 928 | Principal component-derived dietary pattern 12 | GCST90133017 | 6.12 |
| 929 | Body-mass index, inverse-rank normalized | FING00000222 | 6.11 |
| 930 | FCRL3 levels | GCST90469207 | 6.11 |
| 931 | Physical activity | GCST90093322 | 6.11 |
| 932 | ST6GAL1 levels | GCST90470753 | 6.11 |
| 933 | Asthma-related infections | FING00000118 | 6.11 |
| 934 | TAX1BP3 levels | GCST90242976 | 6.11 |
| 935 | Current employment status - Retired | Employment | UKBB00000159 | 6.10 |
| 936 | Diabetes mellitus | endocrine/metabolic | UKBB00000169 | 6.10 |
| 937 | Diabetes (weighted GWA) | GCST90267279 | 6.10 |
| 938 | MEPE levels | GCST90469889 | 6.09 |
| 939 | CEACAM8/VNN2 ratio | GCST90314005 | 6.08 |
| 940 | Loneliness (standard GWA) | GCST90267288 | 6.07 |
| 941 | wg rh intensity-contrast precentral | GCST90003850 | 6.06 |
| 942 | LCN2/PRTN3 ratio | GCST90315307 | 6.04 |
| 943 | Gut bacterial pathway abundance (PYRIDNUCSYN.PWY..NAD.biosynthesis.I..from.aspartate.) | GCST90027638 | 6.04 |
| 944 | CEBPB levels | GCST90468700 | 6.04 |
| 945 | Triglycerides | GCST90018755 | 6.04 |
| 946 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 121) | GCST90320684 | 6.03 |
| 947 | HDAC8 levels | GCST90469438 | 6.03 |
| 948 | IDO1 levels | GCST90469506 | 6.03 |
| 949 | Irritable bowel syndrome | FING00000702 | 6.03 |
| 950 | Asthma and allergy | FING00000115 | 6.02 |
| 951 | Vitamin B12 deficiency anaemia | FING00001441 | 6.01 |
| 952 | PBLD levels | GCST90470163 | 6.00 |
| 953 | PDCD6IP levels | GCST90618969 | 6.00 |
| 954 | XRCC4 levels | GCST90471085 | 6.00 |
| 955 | Coffee type: Ground coffee (include espresso, filter etc) (UKB data field 1508_3) | GCST90041803 | 5.99 |
| 956 | TSC1 levels | GCST90470972 | 5.98 |
| 957 | F-sweetened coffee drink liking (derived food-liking factor) | GCST90094853 | 5.98 |
| 958 | CD20 on IgD- CD24- B cell | GCST90001753 | 5.98 |
| 959 | Right-hemisphere control network to right-hemisphere control network white-matter structural connectivity | GCST90302834 | 5.98 |
| 960 | Lysoalkylphosphatidylcholine (O-24:0) levels | GCST90024197 | 5.97 |
| 961 | IL2RB levels | GCST90469586 | 5.96 |
| 962 | Pollen allergy | FING00001176 | 5.95 |
| 963 | PITHD1 levels | GCST90470239 | 5.95 |
| 964 | Left-hemisphere control network to amygdala white-matter structural connectivity | GCST90302757 | 5.95 |
| 965 | Right ventricular ejection fraction | GCST90268117 | 5.94 |
| 966 | LAYN/VWC2 ratio | GCST90315293 | 5.93 |
| 967 | Ptosis of eyelid | FING00001227 | 5.92 |
| 968 | Lysoalkenylphosphatidylethanolamine (P-20:0) levels | GCST90025460 | 5.92 |
| 969 | Coeliac disease | FING00000312 | 5.92 |
| 970 | F-wine liking (derived food-liking factor) | GCST90094872 | 5.91 |
| 971 | Sleep disorders (PheCode 327) | GCST90475823 | 5.90 |
| 972 | Mean platelet thrombocyte volume (UKB data field 30100) | GCST90468087 | 5.90 |
| 973 | Working memory | GCST90503116 | 5.88 |
| 974 | Neutrophil percentage of granulocytes | GCST004623 | 5.88 |
| 975 | Bacterial pneumoniae | FING00000139 | 5.88 |
| 976 | Percentage of fucosylation of monogalactosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP82) | GCST90668526 | 5.88 |
| 977 | PLXNA4/SRPK2 ratio | GCST90315688 | 5.88 |
| 978 | DTI TBSS L1 Splenium of corpus callosum | GCST90384432 | 5.87 |
| 979 | Polyarthropathies | FING00001180 | 5.87 |
| 980 | CTSZ/HSPG2 ratio | GCST90314318 | 5.86 |
| 981 | CCN2/VEGFC ratio | GCST90313719 | 5.85 |
| 982 | Vitamin and mineral supplements - None of the above | Medication | UKBB00000901 | 5.85 |
| 983 | F9/FURIN ratio | GCST90314747 | 5.84 |
| 984 | Hayfever | GCST90468131 | 5.84 |
| 985 | IDP dMRI ProbtrackX FA fma | GCST90003935 | 5.84 |
| 986 | DNMBP/WWP2 ratio | GCST90314522 | 5.83 |
| 987 | Inflammatory bowel disease, strict (require KELA) | FING00000675 | 5.83 |
| 988 | DMP1 levels | GCST90469007 | 5.82 |
| 989 | Other peripheral nerve disorders (PheCode 351) | GCST90475842 | 5.82 |
| 990 | Gestational [pregnancy-induced] oedema and proteinuria without hypertension | FING00000572 | 5.82 |
| 991 | Exotropia | GCST90572737 | 5.80 |
| 992 | CD6/EZR ratio | GCST90313890 | 5.80 |
| 993 | IGSF21 levels | GCST90469538 | 5.80 |
| 994 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T149 | ECGU000149 | 5.80 |
| 995 | DBNL/VASH1 ratio | GCST90314427 | 5.79 |
| 996 | Takes medication for skin cancer? | GCST90475190 | 5.79 |
| 997 | FXYD5/TMSB10 ratio | GCST90314906 | 5.79 |
| 998 | Type1 diabetes, definitions combined, early onset | FING00001384 | 5.79 |
| 999 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T281 | ECGU000281 | 5.79 |
| 1000 | Breast cancer (PheCode 174) | GCST90435600 | 5.78 |